Skip to main navigation

Menu

Skip to content
  • Investors
    • Overview
    • Stock Information
    • Corporate Governance
    • SEC Filings
    • Fundamentals
    • Shareholder Information
    • Earnings Estimates
    • Ownership Profile
    • Online Investor Kit
    • Press Releases
    • Annual Meeting
    • Events
    • Search Investor Relations
Alnylam
Alnylam
E-mail Alerts  Download Center  RSS  Print  Share
Share this on: Close window
delicious Delicious
Digg Digg
Facebook Facebook
LinkedIn LinkedIn
Twitter Twitter

Download Library

Quickly sort and find the exact file you need here.

Title Type
View Presentation 2 MB
View Presentation 2 MB
View Presentation 871.1 KB
View Presentation 871.1 KB
View Presentation 1.8 MB
View Presentation 1.8 MB
View Presentation 3.9 MB
View Presentation 3.9 MB
View Presentation 3.9 MB
View Presentation 3.9 MB
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss 46.6 KB
Reconciliation of GAAP Net Loss to Non-GAAP Net Loss 46.6 KB
2017 RNAi Roundtable: Revusiran investigation results Presentation 1.3 MB
2017 RNAi Roundtable: Revusiran investigation results Presentation 1.3 MB
Q2 2017 Earnings Presentation 1.7 MB
Q2 2017 Earnings Presentation 1.7 MB
View Presentation 7.9 MB
View Presentation 7.9 MB
2016 Annual Report
2016 Annual Report

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • …
  • Next page Next
  • Last page Last
Displaying 1 - 10 of 53 results

Search

Recent Press Releases

View all releases  RSS

  • Apr 14,2018
    Summary ToggleAlnylam Presents New Positive Clinical Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias
  • Mar 28,2018
    Summary ToggleAlnylam and Collaborators to Present Clinical Study Results in Acute Hepatic Porphyrias (AHPs) at The 53rd International Liver Congress™ of the European Association for the Study of the Liver (EASL)
  • Mar 28,2018
    Summary ToggleAlnylam Presents New Clinical Results from the APOLLO Phase 3 Study of Patisiran at the 16th International Symposium on Amyloidosis
View all releases

: (Common):

Price:
Change (%):
Volume:
Data as of
Copyright NASDAQ. Minimum 15 minutes delay
Learn More
  • twitter
  • linkedin
  • youtube
  • rss

Copyright © 2018 Alnylam Pharmaceuticals, Inc.   ---   All Rights Reserved   ---   Glossary   |   Media Kit   |   Legal   |   Privacy Policy   |   Site Map